National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blumental Sophie, Lajot Adrien, Vandromme Mathil, Lafort Yves, Dockx Yinthe, Denayer Sarah, Wampers Alicia, Nebbioso Andrea, Tilmanne Anne, Mignon Celine, Tuerlinckx David, Rigolle Hanne, Matthijs Inge, Vandersnickt Jan, Hellinckx Johan, Dewulf Jonas, Coppens Katrien, Van Hoorenbeeck Kim, Vanlede Koen, Winters Lore, Seyler Lucie, Parsy Marie-Pierre, Reynders Marijke, Balcaen Mathilde, Urbina Montse, Dauby Nicolas, Chatzis Olga, Naesens Reinout, Dorval Sarah, Ternest Silke, Vanspeybroeck Sophie, Goetghebuer Tessa, Van Ackere Tine, Selimaj Kontoni Valbona, El Bitar Wassim, Holemans Xavier, Bruyere Yveline, Van Brusselen Daan, De Mot Laurane, Raes Marc
Аннотация
METHOD: This survey pooled data from two surveillance systems: the prospective SARI (Severe Acute Respiratory Infection) surveillance (6 hospitals) and the retrospective RSVPed study (25 hospitals). Both used the same case definition and clinical questionnaire to record RSV hospitalizations in children < 5 years. Seasonal incidences and clinical data were compared between seasons 2023-2024 (pre-prevention) and 2024-2025 (first year of prevention).
RESULTS: Our study covered 47% of all pediatric beds in Belgium. We demonstrated a reduction of 39% in pediatric RSV-related hospitalizations and of 57% in RSV-related admissions to intensive care units during 2024-2025 compared to 2023-2024. Incidences decline mainly concerned infants < 6 months, without changes in older age groups. Furthermore, savings in health care resources were observed through shorter length of stay and significantly less use of non-invasive ventilatory support and nutritional support among hospitalized cases in 2024-2025.
CONCLUSION: Following implementation of nirsevimab, a substantial reduction in RSV paediatric burden was observed in Belgium. However, efforts should be made to increase the uptake of preventive tools in our country to achieve better effectiveness. This study also highlights the major role of a national network to monitor efficacy of prevention over time.
CLINICAL TRIAL NUMBER: Not applicable.